US 5283173A
· Fields et al.
· 1994
[cited by applicant]
US 5420032A
· Marshall et al.
· 1995
[cited by applicant]
US 5468614A
· Fields et al.
· 1995
[cited by applicant]
US 6410319B1
· Raubitschek et al.
· 2002
[cited by applicant]
US 6833252B1
· Dujon et al.
· 2004
[cited by applicant]
US 7446191B2
· Jensen
· 2008
[cited by applicant]
US 7514537B2
· Jensen
· 2009
[cited by applicant]
US 8697359B1
· Zhang
· 2014
[cited by applicant]
US 8822647B2
· Jensen
· 2014
[cited by applicant]
US 9574000B2
· Langermann et al.
· 2017
[cited by applicant]
US 20060078552A1
· Arnould et al.
· 2006
[cited by applicant]
US 20060153826A1
· Arnould et al.
· 2006
[cited by applicant]
US 20060206949A1
· Arnould et al.
· 2006
[cited by applicant]
US 20110189141A1
· Kieback et al.
· 2011
[cited by applicant]
US 20110243972A1
· Jaffee
· 2011
[cited by applicant]
US 20140186843A1
· Zhang et al.
· 2014
[cited by applicant]
WO WO9709433A1
· 1997
[cited by applicant]
WO 2007002811A2
· 2007
[cited by applicant]
WO WO2013025779A1
· 2013
[cited by applicant]
WO WO2014031687A1
· 2014
[cited by applicant]
WO WO2015071474A2
· 2015
[cited by applicant]
WO 2015095895A1
· 2015
[cited by applicant]
WO WO2016040724A1
· 2016
[cited by applicant]
WO WO2016054638A1
· 2016
[cited by applicant]
WO 2016069647A1
· 2016
[cited by applicant]
WO WO2016134333A1
· 2016
[cited by applicant]
WO 2016161273A1
· 2016
[cited by applicant]
WO WO2017021526A1
· 2017
[cited by applicant]
WO 2017096331A1
· 2017
[cited by applicant]
Dunn et al., “Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity,”
[cited by applicant]
Lee et al., “Current management and novel agents for malignant melanoma,”
[cited by applicant]
Legut et al., “CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells,”
[cited by applicant]
Sharkey et al., “CD4+ T-Cell Recognition of Mutated B-RAF in Melanoma Patients Harboring the V599E Mutation,”
[cited by applicant]
Veatch et al., “Tumor-infiltrating BRAF
[cited by applicant]
Walseng et al., “A TCR-based Chimeric Antigen Receptor,”
[cited by applicant]
GenBank, “T-cell receptor alpha chain, partial [
[cited by applicant]
Kobayashi et al., “A new cloning and expression system yields and validates TCRs from blood lymphocytes of patients with cancer within 10 days,”
[cited by applicant]
Abbas et al., “Cellular and Molecular Immunology,” Third Edition, pp. 149, 155, 250, 266, 413, 1997. (7 pages).
[cited by applicant]
Altschul et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Research 25(17):3389-3402, Jul. 16, 1997.
[cited by applicant]
Argast et al., “I-Ppol and I-Crel Homing Site Sequence Degeneracy Determined by Random Mutagenesis and Sequential in Vitro Enrichment,”
[cited by applicant]
Ashworth et al., “Computational redesign of endonuclease DNA binding and cleavage specificity,”
[cited by applicant]
Belfort et al., “Homing endonucleases: keeping the house in order,”
[cited by applicant]
Brentjens et al., “Genetically Targeted T Cells Eradicates Systemic Acute Lymphoblastic Leukemia Xenografts,”
[cited by applicant]
Cavallo et al., “2011: the immune hallmarks of cancer,”
[cited by applicant]
Chapuis et al., “Abstract LB-136: IL-21-derived melanoma-reactive CTL combined with anti-CTLA4 persist, acquire central memory characteristics, and mediate tumor regression in patients with metastatic melanoma,”
[cited by applicant]
Chapuis et al., “Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype,”
[cited by applicant]
Chapuis et al., “Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients,”
[cited by applicant]
Chevalier et al., “Design, Activity, and Structure of a Highly Specific Artificial Endonuclease,”
[cited by applicant]
Chothia, et al., “The outline structure of the T-cell ab receptor,”
[cited by applicant]
Cole et al., “CD8: Adhesion Molecule, Co-Receptor and Immuno-Modulator,”
[cited by applicant]
Dangaj et al., “Novel Recombinant Human B7-H4 Antibodies Overcome Tumoral Immune Escape to Potentiate T-Cell Antitumor Responses,” Cancer Res 73(15):4820-4829, Aug. 1, 2013.
[cited by applicant]
Desjarlais et al., “Use of a zinc-finger consensus sequence framework and specificity rules to design specific DNA binding proteins,”
[cited by applicant]
Dossett et al., “Adoptive Immunotherapy of Disseminated Leukemia With TCR-transduced, CD8+ T Cells Expressing a Known Endogenous TCR,”
[cited by applicant]
Dudley et al., “Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma,”
[cited by applicant]
Dujon et al., “Mobile introns: definition of terms and recommended nomenclature,”
[cited by applicant]
Dunbar et al., “ANARCI: antigen receptor numbering and receptor classification,”
[cited by applicant]
Engels et al., “Retroviral Vectors for High-Level Transgene Expression in T Lymphocytes,”
[cited by applicant]
Epinat et al., “A novel engineered meganuclease induces homologous recombination in yeast and mammalian cells,”
[cited by applicant]
Floros et al., “Anticancer Cytokines: Biology and Clinical Effects of IFN-α2, IL-2, IL-15, IL-21, and IL-12,”
[cited by applicant]
Frasca et al., “BRAF(V600E) mutation and the biology of papillary thyroid cancer,” Endocrine-Related Cancer 15:191-205, 2008.
[cited by applicant]
Gao et al., “Molecular interactions of coreceptor CD8 and MHC class I: the molecular basis for functional coordination with the T-cell receptor,”
[cited by applicant]
GenBank, “
[cited by applicant]
Gimble et al., “Substrate Recognition and Induced DNA Distortion by the PI-Scel Endonuclease, an Enzyme Generated by Protein Splicing,”
[cited by applicant]
Green et al., “Mitochondria and Apoptosis,”
[cited by applicant]
Gros et al., “Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients,”
[cited by applicant]
Hanahan et al., “Hallmarks of Cancer: The Next Generation,”
[cited by applicant]
Hanahan et al., “The Hallmarks of Cancer,”
[cited by applicant]
Harris et al., “Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors,” Trends in Pharmacological Sciences 37(3):220-230, Mar. 2016.
[cited by applicant]
Ho et al., “In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire,”
[cited by applicant]
Janeway et al., “Immunobiology: The Immune System in Health and Disease,” 3rd Ed., Current Biology Publications, p. 4:33, 1997. (14 pages).
[cited by applicant]
Jasin, “Genetic manipulation of genomes with rare-cutting endonucleases,”
[cited by applicant]
Jinek et al., “A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity,”
[cited by applicant]
Johnson et al., “Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen,”
[cited by applicant]
Jones et al., “Lentiviral Vector Design for Optimal T Cell Receptor Gene Expression in the Transduction of Peripheral Blood Lymphocytes and Tumor-Infiltrating Lymphocytes,”
[cited by applicant]
Jores et al., “Resolution of hypervariable regions in T-cell receptor β chains by a modified Wu-Kabat index of amino acid diversity,”
[cited by applicant]
Kabat et al., “Sequences of Proteins of Immunological Interest,” Fifth Edition, U.S. Department of Health and Human Services, 1991. (84 pages).
[cited by applicant]
Kim et al., “Analysis of the Paired TCR a-and B-chains of Single Human T Cells,”
[cited by applicant]
Koboldt et al., “VarScan 2: Somatic mutation and copy No. alteration discovery in cancer by exome sequencing,”
[cited by applicant]
Kreiter et al., “Increased Antigen Presentation Efficiency by Coupling Antigens to MHC Class I Trafficking Signals,”
[cited by applicant]
Kuball et al., “Facilitating matched pairing and expression of TCR chains introduced into human T cells,”
[cited by applicant]
Kyrgidis et al., “Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications,”
[cited by applicant]
Larsson et al., “Local co-administration of gene-silencing RNA and drugs in cancer therapy: State-of-the art and therapeutic potential,” Cancer Treatment Reviews 55:128-135, 2017.
[cited by applicant]
Leen et al., “Improving T Cell Therapy for Cancer,” Annu. Rev. Immunol. 25:243-265, 2007.
[cited by applicant]
Lefranc et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,”
[cited by applicant]
Lehninger, Lehninger (eds.), Biochemistry, The Molecular Basis of Cell Structure and Function, Worth Publishers, Inc., New York, N.Y., 1975, pp. 45-52. (12 pages).
[cited by applicant]
Li et al., “Fast and accurate short read alignment with Burrows-Wheeler transform,”
[cited by applicant]
Li et al., “RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome,”
[cited by applicant]
Li, “Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM,” 2013. (3 pages).
[cited by applicant]
Lim et al., “Hepatitis B virus nuclear export elements: RNA stem-loop α and β, key parts of the HBV post-transcriptional regulatory element,”
[cited by applicant]
Liu et al., “Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity,” Blood 115(17):3520-3530, Apr. 29, 2010.
[cited by applicant]
Manici et al., “Melanoma Cells Present a MAGE-3 Epitope to CD4+ Cytotoxic T Cells in Association with Histocompatibility Leukocyte Antigen DR11,”
[cited by applicant]
Mautino et al., “NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy,” American Association for Cancer Research 104th Annual Meeting, Apr. 6-10, 2013 (Abstract only). (1…
[cited by applicant]
Munson et al., “Identification of shared TCR sequences from T cells in human breast cancer using emulsion RT-PCR,”
[cited by applicant]
Penix et al., “Two Essential Regulatory Elements in the Human Interferon γ Promoter Confer Activation Specific Expression in T Cells,”
[cited by applicant]
Perler et al., “Protein splicing elements: inteins and exteins—a definition of terms and recommended nomenclature,”
[cited by applicant]
Petersdorf et al., “The International Histocompatibility Working Group in Hematopoietic Cell Transplantation,”
[cited by applicant]
Porteus et al., “Gene targeting using zinc finger nucleases,”
[cited by applicant]
Pâques et al., “Meganucleases and DNA Double-Strand Break-Induced Recombination: Perspectives for Gene Therapy,”
[cited by applicant]
Quezada et al., “Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts,”
[cited by applicant]
Ramos et al., “Oncotator: cancer variant annotation tool,”
[cited by applicant]
Redmond et al., “Single-cell TCRseq: paired recovery of entire T-cell alpha and beta chain transcripts in T-cell receptors from single-cell RNAseq,”
[cited by applicant]
Ren et al., “Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition,”
[cited by applicant]
Riddell et al., “The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells,”
[cited by applicant]
Robins et al., “Comprehensive assessment of T-cell receptor B-chain diversity in αβ T cells,”
[cited by applicant]
Robins et al., “Overlap and Effective Size of the Human CD8+ T Cell Receptor Repertoire,”
[cited by applicant]
Robins et al., “Ultra-sensitive detection of rare T cell clones,”
[cited by applicant]
Sadelain et al., The Basic Principles of Chimeric Antigen Receptor Design,
[cited by applicant]
Sambrook et al., “Molecular Cloning: A Laboratory Manual,” Second Edition, Cold Spring Harbor Laboratory Press, 1989. (3 pages).
[cited by applicant]
Scatchard et al., “The Attractions of Proteins for Small Molecules And Ions,”
[cited by applicant]
Schmitt et al., “T Cell Receptor Gene Therapy for Cancer,”
[cited by applicant]
Scholten et al., “Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells,” Clinical Immunology 119:135-145, 2006.
[cited by applicant]
Shi et al., “Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy,”
[cited by applicant]
Sommermeyer et al., “Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo,”
[cited by applicant]
Stone et al., “A novel T cell receptor single-chain signaling complex mediates antigen- specific T cell activity and tumor control,”
[cited by applicant]
Stone et al., “Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies,”
[cited by applicant]
Stromnes et al., “Re-adapting T cells for cancer therapy: from mouse models to clinical trials,”
[cited by applicant]
Sun et al., “Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help,”
[cited by applicant]
Sussman et al., “Isolation and Characterization of New Homing Endonuclease Specificities at Individual Target Site Positions,”
[cited by applicant]
Terentis et al., “The Selenazal Drug Ebselen Potently Inhibits Indoleamine 2,3-Dioxygenase by Targeting Enzyme Cysteine Residues,”
[cited by applicant]
Thompson et al., “cis-Acting Sequences Required for Inducible Interleukin-2 Enhancer Function Bind a Novel Ets-Related Protein, Elf-1,”
[cited by applicant]
Till et al., “Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells,” Blood 112(6):2261-2271, Sep. 15, 2008.
[cited by applicant]
Todd et al., “Transcription of the Interleukin 4 Gene Is Regulated by Multiple Promoter Elements,”
[cited by applicant]
Torikai et al., “A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR,” Blood 119(24):5697-5705, Jun. …
[cited by applicant]
Torikai et al., “Genetic editing of HLA expression in hematopoietic stem cells to broaden their human application,”
[cited by applicant]
Torikai et al., “Toward eliminating HLA class I expression to generate universal cells from allogeneic donors,” Blood 122(8):1341-1349, Aug. 22, 2013.
[cited by applicant]
Tran et al., “Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer,”
[cited by applicant]
UniProt, “BRAF_Human,” sequence ID No. P15056, downloaded Nov. 2, 2022. (24 pages).
[cited by applicant]
UniProt, “CD4_Human,” sequence ID No. P01730, downloaded Nov. 2, 2022. (16 pages).
[cited by applicant]
UniProt, “CD8A_Human,” sequence ID No. P01732, downloaded Nov. 2, 2022. (9 pages).
[cited by applicant]
UniProt, “CD8B_Human,” sequence ID No. P10966, downloaded Nov. 2, 2022. (7 pages).
[cited by applicant]
Van der Auwera et al., “From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline,”
[cited by applicant]
Wang et al., “Optimizing Adoptive Polyclonal T Cell Immunotherapy of Lymphomas, Using a Chimeric T Cell Receptor Possessing CD28 and CD137 Costimulatory Domains,” Human Gene Therapy 18:712-725, Aug. 2007.
[cited by applicant]
Warren et al., “Exhaustive T-cell repertoire sequencing of human peripheral blood samples reveals signatures of antigen selection and a directly measured repertoire size of at least 1 million clonotypes,”
[cited by applicant]
Williams et al., “Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells,”
[cited by applicant]
Wilson, “Analyzing Biomolecular Interactions,”
[cited by applicant]
Wolfe et al., “Analysis of Zinc Fingers Optimized via Phage Display: Evaluating the Utility of a Recognition Code,” J. Mol. Biol. 285:1917-1934 (1999).
[cited by applicant]
Wolff et al., “Monoclonal Antibody Homodimers: Enhanced Antitumor Activity in Nude Mice,” Cancer Research 53:2560-2565, Jun. 1, 1993.
[cited by applicant]
Xie et al., “sgRNAcas9: A Software Package for Designing CRISPR sgRNA and Evaluating Potential Off-Target Cleavage Sites,”
[cited by applicant]
Yee et al., “Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells,”
[cited by applicant]
Henkart et al., “Chapter 36: Cytotoxic T-Lymphocytes,” Fundamental Immunology, Lippincott Williams & Wilkins, Philadelphia, PA, 2003, pp. 1127-1150.
[cited by applicant]
Coffin, “Chapter 58: Retroviridae: The viruses and their replication,” Fundamental Virology, Third Edition, edited by Fields et al., Lippincott-Raven Publishers, Philadelphia, 1996, 1767-1847.
[cited by applicant]